Empagliflozin improves aortic injury in obese mice by regulating fatty acid metabolism
Empagliflozin has been shown in clinical studies to lower the risk of adverse cardiovascular events. Using proteomics, the current study aims to determine whether empagliflozin reduces aortic alterations in obese mice and to investigate its molecular mechanism of action.
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , , , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
De Gruyter
2024-08-01
|
| Σειρά: | Open Medicine |
| Θέματα: | |
| Διαθέσιμο Online: | https://doi.org/10.1515/med-2024-1012 |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|